Twice-a-Day Bismuth-Containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Trial of 10 and 14Days

Helicobacter

Volumn 16, Issue 4, 2011, Pages 295-300

  Dore, Maria Pina ^a,b   Farina, Valentina ^a   Cuccu, Marianna ^a   Mameli, Laura ^a   Massarelli, Giovanni ^a   Graham, David Y ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bismuth; Helicobacter pylori; Treatment

Indexed keywords

BISMUTH CITRATE; METRONIDAZOLE; PANTOPRAZOLE; TETRACYCLINE;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; ERADICATION THERAPY; EVENING DOSAGE; FATIGUE; FEMALE; GLOSSITIS; HELICOBACTER INFECTION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH PAIN; TREATMENT DURATION; UREA BREATH TEST; VAGINITIS; VOMITING; WEAKNESS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; BISMUTH; BREATH TESTS; DRUG THERAPY, COMBINATION; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HISTOCYTOCHEMISTRY; HUMANS; ITALY; MALE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRACYCLINE; TIME FACTORS; TREATMENT OUTCOME; UREA; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 79960457815     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2011.00857.x     Document Type: Article

References (28)

1. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter priori infection-The Maastricht 111 Consensus Report. Gut 2007;56:772-81.
2. Realdi G, Dore MP, Piana A, et al. Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. Helicobacter 1999;4:106-12.
3. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-53.
4. Yamaoka Y, Graham DY, Lu H. Should triple therapy for Helicobacter pylori infection be abandoned as no longer effective? Gastroenterology 2008;4:65-7.
5. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infection. Nat Clin Pract Gastroenterol and Hepal 2008;5:321-31.
6. Dore MP, Marras L, Maragkoudakis E, Nieddu S, Manca A, Graham DY, Realdi G. Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen. Helicobacter 2003;8:307-9.
7. Laine L, Hunt R, El Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562-7.
8. Malfertheiner P, Megraud F, Giguere M, Riviere M. Quadruple therapy with bismuth subcitrate potassium, metronidazole, tetracycline, and omeprazole is superior to triple therapy with omeprazole, amoxicillin, and clarithromycin in the eradication of Helicobacter pylori. Gastroenterology 2010;138(Suppl 1):S-33.
9. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004;20:1071-82.
10. Dore MP, Graham DY, Mele R, Marras L, Nieddu S, Manca A, Realdi G. Colloidal bismuth subcitrate--containing twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol 2002;97:857-60.
11. Dominguez-Munoz JE, Leodolter A, Sauerbruch T, Malfertheiner P. A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection. Gut 1997;40:459-62.
12. Fagan T. Quick basic program for exact and mid-P confidence intervals for a binomial proportion. Comput Biol Med 1996;26:263-7.
13. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Rifabutin- and furazolidone--containing Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005;21:91-6.
14. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin--containing triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther 2005;22:45.
15. Gisbert JP, Gonzalez L, Calvet X. Systematic review and meta-analysis: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics in Helicobacter pylori eradication. Helicobacter 2005;10:157-71.
16. Graham DY, Opekun AR, Hammoud F, Yamaoka Y, Reddy R, Osato MS, El-Zimaity HM. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003;17:1229-36.
17. Borody TJ, Cole P, Noonan S, Morgan A, Lenne J, Hyland L, Brandl S, Borody EG, George LL. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989;151:431-5.
18. George LL, Borody TJ, Andrews P, Devine M, Moore Jones D, Walton M, Brandl S. Cure of duodenal ulcer after eradication of Helicobacter pylori. Med J Aust 1990;153:145-9.
19. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010;362:1597.
20. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007;26:343.
21. De Boer WA. Bismuth triple therapy: still a very important drug regimen for curing Helicobacter infection. Eur J Gastroenterol Hepatol 1999;11:697-700.
22. Graham DY, Hoffman J, El-Zimaity HMT, Graham DP, Osato M. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11:935-8.
23. Graham DY, Belson G, Abudayyeh S, Osato MS, Dore MP, El-Zimaity HM. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States. Dig Liver Dis. 2004;36:384-7.
24. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States: Results from 224 patients. Dig Dis Sci 2000;45:265-71.
25. Buring SM, Winner LH, Hatton RC, Doering PL. Discontinuation rates of Helicobacter pylori treatment regimens: a meta-analysis. Pharmacotherapy 1999;19:324-32.
26. Dore MP, Maragkoudakis E, Pironti A, Tadeu V, Tedde R, Realdi G, Delitala G. Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly. Helicobacter 2006;11:52-5.
27. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-8.
28. Graham DY. Efficient Identification and Evaluation of Effective Helicobacter pylori Therapies. Clin Gastroenterol Hepatol 2009;7:145-8.